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One ofthe major components found in the granules of CTL is pore-forming pro-
tein (PFP)' (perforin or cytolysin) (1-4), a C-9 like protein, which in the presence
of Ca2+ polymerizes to form transmembrane channels in target cells. Resting CTL
that exhibit no cytolytic activity contain little or no PFP; however, synthesis of PFP
and demonstrated cytotoxic activity can be induced in human PBMC by incubation
with anti-CD3 mAb (OKT3) or IL-2 for several days (5, 6).
The recent cloning of PFP cDNA and use of PFP cDNA probes have indicated
that PFP mRNA is expressed specifically in cytolytic lymphocytes regardless ofwhether
they were generated in vivo or cultured in vitro (3, 4, 7). In particular, human PBMC
expressed low amounts of PFP mRNA; however, when cultured with IL-2, these
levels increased fivefold within 24 h and preceded an increase in cytotoxicity by 12 h (3).
Despite these findings it was still unclear whether IL-2 or anti-CD3 mAb could
directly induce PFP expression in T cells and large granular lymphocytes (LGL).
Our studies have investigated PFP mRNA expression in purified human peripheral
blood CD3 - LGL, CD3+ T cells and their subsets (CD4+/CD8+) stimulated with
IL-2, OKT3 mAb, PMA, and ionomycin.
Materials and Methods
Preparation ofLymphoid Cells.
￿
PBMC were separated on Ficoll-Hypaque as described (8).
Leukocyte suspensions were washed with HBSS and were resuspended in RPMI 1640 con-
taining 10% heat-inactivated FCS. Adherent cells (monocytes and B cells) were removed by
incubation onplastic dishes and nylon wool. To enable crosslinking ofthe OKT3 mAb, mono-
cytes were collected by treatment of the plastic dishes with versene-EDTA and mixed (8%)
with purified CD3+ lymphocytes. Highly enriched populations of CD3' T cells (>90%) and
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CD3- LGL (>95%) from PBMC were obtained by centrifugation of nylon wool-passed cells
on discontinuous density gradients of Percoll (Pharmacia Fine Chemicals, Uppsala, Swe-
den). Subsequent SRBC rosetting of CD56-enriched Percoll fractions was used to remove
contaminating T cells to obtain the CD3 -/LGL populations (9). T cell subsets (CD4'/CD8')
were negatively selected by adherence of mAb' (OKT4 or OKT8) cells to F(ab')2 anti-
mouse Ig (Cappel Laboratories, Malvern, PA)-coated petridishes (Falcon Labware, Oxnard,
CA) (10). Upon purification, the populations were analyzed by flow cytometry to determine
the extent of contamination. Cells were phenotyped by using phycoerythrin- or FITC-
conjugated mAbs; anti-Leu-3a (IgGI, anti-CD4); anti-Leu-2a (IgGI, anti-CD8); anti-Leu-4
(IgGI, anti-CD3); anti-Leu-19 (IgGI, anti-CD56); anti-Leu Ila (3G8, IgGI, anti-CD16); and
anti-Leu Ilb (Vep 13, IgM, anti-CD16) (Becton Dickinson Immunocytometry Systems, Moun-
tain View, CA). Two color fluorescence measurements were performed on a FACScan IV
flow cytometer (Becton Dickinson).
Lymphocyte Stimulation.
￿
Isolated T cells and LGL were cultured in RPMI 1640 medium
supplemented with 2 MM L-glutamine, 2% heat-inactivated FCS, 100 U/ml penicillin; 100
1Lg/ml streptomycin, and 6 mM Hepes buffer (pH 7 .3) (Gibco Laboratories, Grand Island,
NY). Cultures (1-2 x 106/ml) were stimulated with PMA (Sigma Chemical Co., St. Louis,
MO) at 10 ng/ml, ionomycin (Calbiochem-Behring Diagnostics, La Jolla, CA) at 3 Wg/ml,
human rIL-2 (Cetus Corp., Emeryville, CA) at 0-6,000 U/ml or OKT3 mAb at 0.5-10 ug/ml.
Monoclonal Antibodies.
￿
TU27 mAb reacts with the p75 subunit of the IL-2 receptor and
inhibits the binding of IL-2 to this receptor (11). H-31 mAb reacts with the p55 IL-2 receptor
and inhibits IL-2 binding to this subunit (12).
Proliferation Assay.
￿
Triplicate cultures of 2 x 105 CD3' CD56 - T cells in 200 JAI of media
(as above) were seeded in a 96-microwell plate and were stimulated with IL-2, OKT3 mAb,
PMA, and ionomycin as above. Cultures were incubated at 37 °C in 51/ 1o C02 for 10 h.
s[H]TdR (New England Nuclear, Boston, MA) (6.7 Ci/mmol) incorporation was determined
during the last 4 h of culture (1 uCi/well).
RNAAnalyses.
￿
Total cytoplasmic RNA was purified from T cells and LGL by the method
of Chomczynski et al. (13). For Northern analysis RNA was subjected to electrophoresis on
a 0.8% agarose formaldehyde gel, then transferred to Nytran (Schleicher & Schuell, Keene,
NH). All blots were hybridized to '2P-labeled human PFP cDNA, human IFN-'y cDNA or
chicken /3-actin cDNA as described previously (14). The blots were then exposed to Kodak
X-OMAT AR film for 0-7 d at -70°C . Comparative levels of PFP mRNA expression were
determined from the film using a gel scanner (ISCO, Lincoln, NE). The human PFP cDNA
was isolated from a cDNA library constructed from the NK-like clone YTN-10 (15). The
human IFN-,y cDNA was obtained from Dr. G. Ricca (Rorer Biotechnology, King of Prus-
sia, PA) and the chicken (3-actin cDNA was from Dr. D. W. Cleveland (Princeton University,
Princeton, NJ).
IFN-y . Assay.
￿
Human IFN--y was assayed by RIA (Centocor, Malvern, PA) of culture su-
pernatants obtained after treatment of cells with the indicated agents.
IL-2 Assay.
￿
Human IL-2 was assayed by an ELISA of culture supernatants (Collabora-
tive Research Incorporated, Bedford, MA) obtained aftertreatment ofcells with OKT3 mAb.
Cytotoxicity Assay.
￿
Cytotoxicity was measured in a standard 4-h "Cr-release assay (7). The
heteroconjugated antibody-dependent cytotoxicity assay was performed as described previ-
ously (16).
Results
IL-2 Induction of PFP mRNA Expression in T Cells.
￿
Upon purification of CD3'
lymphocytes from human peripheral blood, flow cytometry determined this popula-
tion to exhibit >90% reactivity with the anti-Leu-4 mAb and <3% reactivity with
the anti-Leu-19 mAb. The effect of IL-2 on PFP mRNA expression in these CD3 +
lymphocytes was examined using Northern blot analysis oftheir total cellular RNA.
Induction of PFP mRNA expression occurred in T cells that were cultured with
1,000 U/ml of IL-2 (Fig. 1). With 4 h of IL-2 stimulation, levels of PFP mRNASMYTH ET AL .
￿
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FIGURE 1 .
￿
Kinetics of PFPmRNA expression
in human peripheral blood CD3' CD56 - lym-
phocytes . This population was cultured for var-
ious periods of time (2-24 h) in the presence of
IL-2 (-, unstimulated for 24 h) . Total cellular
RNA was isolated from the cultured cells and
Northern blot analysis wasperformed on 10 kg
ofRNA . The filter was hybridized with a cDNA
probe for (A)humanPFP and (B) chicken O-actin .
were increased fourfold above those of the unstimulated T cell control . Maximal
expression of PFP mRNA was observed after 6 h incubation with IL-2 (seven to
eight times control levels), followed by a decline back to lower steady-state levels at
later time points . Clearly induction ofPFPmRNA inT cells was also observed with
lower concentrations ofIL-2 (>50 U/ml), although theincrease was dose dependent
and variable between donors (data not shown) .
To monitor experiments for the contribution of <3% contaminating CD3 - LGL
or the possible preactivation of some of the donor's CD3+ T cells, an RIA for hu-
man IFN-y production was performed on the supernatants of these IL-2-stimu-
latedT cell cultures and the Northern blot (from Fig . 1) was hybridized with a hu-
man IFN-ycDNA probe . Consistent with T cells requiring two signals for IFN-y
production (17), neither human IFN-y activity (<1 U/ml) nor 1.3-kb human IFN-y
mRNA were detected fromTcell cultures stimulated with IL-2 alone (data notshown) .
This indicated that the contribution of contaminating LGL or preactivated T cells
was minimal in these T cell cultures .
To examine whether IL-2 was inducing PFPmRNA expression that required si-
multaneous T cell proliferation, we compared IL-2 and otherstimuli fortheir effect
on s[H]TdR uptake in CD3 + lymphocytes (Fig. 2) . Previously determined positive
control combinations ofPMA and ionomycin orOKT3mAb and accessorymono-
cytes (18) predictably inducedT cell DNA synthesis . By comparison, IL-2-treated
T cells did not synthesize DNA (Fig . 2) . In addition, T cells stimulated by IL-2
for 6 h in the absence or presence of cycloheximide (CHX) indicated that IL-2-in-
duced PFP mRNA expression in the absence ofnew protein synthesis (i.e ., in the
presence ofCHX) (data not shown) . Therefore, it appeared that humanperipheral
blood CD3 + lymphocytes contained low but detectable amounts ofPFPmRNA that
could be directly and rapidly induced by IL-2 in the absence of cellular prolifera-
tion, or new protein synthesis .1272
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FIGURE 2 .
￿
Proliferation ofT cells after stimu-
lation with IL-2, PMA, OKT3 mAb or PMA
and ionomycin (IONO) . A total of 2 x 10'
purified CD3' CD56 - T cells were stimulated
with IL-2 (1,000 U/ml), PMA(10 ng/ml), acom-
bination ofPMA (10 ng/ml) and ionomycin (3
pg/ml), orOKT3 mAb (10 pg/ml) plus8% mono-
cytes . After6 h, cultures were pulsed for 4 h with
'[H]TdR . Counts were calculated as the mean ±
SEM (triplicate determinations) .
PFP mRNA Expression in IL-2-stimulated CD4' and CD8' T Cell Subsets .
￿
Having
established that IL-2 directly induced PFPmRNA in whole unfractionated popula-
tions ofCD3' T cells, it was important to determine whether IL-2 induction was
specifically occurring in both or either of the CD4+ and CD8' subsets . Separated
CD4' and CD8+ subsets from CD3* T cells ofhuman peripheral blood were ana-
lyzed by flow cytometry for their reactivity with the anti-CD4 (anti-Leu-3a) mAb
and the anti-CD8 (anti-Leu-2a) mAb. Three populations (unfractionated, CD4',
and CD8') were stimulated with 1,000 U/ml IL-2 for 6 h and their PFP mRNA
expression was examined byNorthern analysis (Fig . 3) . Densitometric quantitation
of the 2.9-kb PFP mRNA bands revealed that the population enriched for CD8'
FIGURE 3 .
￿
Expression ofPFPmRNA in human pe-
ripheral blood T cell subsets stimulated with IL-2 .
Fractionated CD4' (81% CD4*, 6% CD8'), CD8'
(68% CD8', 20% CD4'), and whole unfractionated
(55% CD4', 34% CD8')T cells were cultured for
6 h in the presence of IL-2 (1,000 U/ml) . Total cel-
lular RNAwas isolated and Northern blot analysis
was performed on 10 pg ofRNA. The filter was hy-
bridized with acDNA probe for (A)humanPFPand
(B) chicken 0-actin .SMYTH ET AL .
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cells by CD4+ depletion (68% CD8*, 20% CD4+) had a 10-fold greater expression
than the CD4+ population (6% CD8*, 81% CD4*), and 1-2-fold greater PFP
mRNA expression than the unfractionated control population (5550 CD4*, 34%
CD8*) (Table I). These data demonstrate that IL-2 predominantly induces PFP
mRNA expression in CD3* CD8* lymphocytes .
IL-2 Induction of T Cell PFPmRNA via the p75 IL-2 Receptor .
￿
The expression of
functional IL-2 receptor on peripheral blood T cell populations, has previously been
confirmed by TU27 (anti-p75 IL-2 receptor) and H-31 (anti-p55 IL-2 receptor) mAbs
in flow cytometric analysis . CD8 * T cells express the p75, but not the p55, IL-2
receptor (16) . To determine the involvement of p55 and p75 IL-2 receptors in the
rapid and direct induction ofPFP mRNA in human peripheral blood T cells, PFP
mRNA expression was examined after culturing CD3* T cells with IL-2 (6 h, 1,000
U/ml) in the presence/absence of 100 hg/ml H-31 and/or TU27 mAbs . As shown
in Fig . 4 TU27 mAb alone or in combination with H-31 mAb dramatically inhib-
ited IL-2 induction of PFP mRNA in T cells . By contrast, the H-31 mAb alone
had no effect on IL-2 induction of PFP mRNA in T cells (Fig. 4) . A cytotoxicity
assay performed in parallel with the same T cells after a 16-h culture indicated that
the induction ofcytolytic activity was indeed abrogated by the TU27 (anti-p75 IL-2
receptormAb) but not by the H-31 (anti-p55 IL-2 receptormAb) (data not shown) .
In conclusion, these data indicate that the p75 IL-2 receptor is directly involved in
IL-2 induction of T cell PFP mRNA and cytotoxicity.
OKT3 mAb Induction ofPFP mRNA Expression in T Cells.
￿
The OKT3 mAb (10
Aglml) could induce PFPmRNA expression in CD3 + lymphocytes in the presence
of 8% adherent monocytes (Fig . 5 A) . Elevated levels ofPFPmRNA were observed
in T cells after 9 h of OKT3 stimulation (greater than five times control levels),
while peak PFPmRNA expression occurred aftermore than 24 h of culture inOKT3
mAb (-13 times control levels) (Fig . 5 A) . The OKT3 mAb was also used at doses
of 0.5, 1, and 5 Aglml and was found to induce T cell PFP mRNA expression (data
not shown) . Therefore it appeared that induction ofPFPmRNA by OKTT mAb
was direct in CD3 * lymphocytes, although in contrast to IL-2 stimulation (Fig . 1),
no increase in PFP mRNA expression was detected within 4 h of the addition of
OKT3 mAb (Fig . 5 A) . An ELISA forhuman IL-2 revealed thatno detectable IL-2
was observed in cultures ofT cells stimulated with OKT3 mAb for 9 h or less ; how-
ever, the supernatants of 24-h OKT3 mAb-treated CD3* T cells contained 30 U/ml
IL-2 . The absence of detectable IL-2 in OKT3 mAb-treated T cell cultures after
9 h suggests that induction of PFP mRNA by OKT3 mAb precedes any possible
FIGURE 4 .
￿
The effect ofanti-IL-2-R mAbs
on IL-2 induced PFPmRNA expression in
human peripheral blood CD3* CD56 - T
cells .T cells were cultured with (+) orwithout
(-) IL-2 (1,000 U/ml) in the presence or ab-
sence (-)of1001cg/ml ofanti-p55 IL-2-R (H-
31) mAb and/or anti-p75 IL-2 receptor
(TU27) mAb for6 h at 37°C . Total cellular
RNA was isolated from the cultured cells and
Northern blot analysis was performed on 10
kg of RNA. The filter was hybridized with 32P-labeled human PFP cDNA .1274
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FIGURE 5 .
￿
Kinetics of expression ofPFP, IFN-,y, and/3-actinmRNA in human peripheral blood
CD3' CD56 - T cells . T cells were treated : (A) lane 1, 24 h unstimulated ; lane 2, 4 h OKT-3
mAb; lane 3, 9 h OKT3 mAb; lane 4, 9 h IL-2 ; lane 5, 9 h OKT-3 mAb and IL-2 ; lane 6,
24 hOKT3mAb. (B) Lane 1, 6 hPMA; lane 2, 6 h ionomycin ; lane 3, 6 hPMA and ionomycin ;
lane 4, 24 hPMA ; lane 5, 24 h ionomycin ; lane 6, 24 h PMA and ionomycin ; lane 7, 24 h un-
stimulated . All the treatments in panel A included 8 17b monocytes anddoses were as follows : OKT-3
mAb (10 Wg/ml), IL-2 (1,000 U/ml), PMA (10 ng/ml), and ionomycin (3 14g/ml) . Total cellular
RNA was isolated from the cultured cells and Northern blot analysis was performed . Both filters
A and B were hybridized with ' 2P-labeled human PFP cDNA; then the filters were stripped by
washing with boiling 0.01 x SSC, 0.01% SDS and rehybridized with human IFN- ,y cDNA and
chicken /3-actin cDNA, respectively. The IL-2 levels in the supernatants of OKT-3 mAb-stimu-
lated T cells were (A) lane 1, 0 U/ml ; lane 2, 0 U/ml ; lane 3 0 U/ml ; and lane 6, 30 U/ml . It
should be noted that the increased level of PFPcDNA hybridized in B (PMA, 6 h ; lane 1) could
be accounted for by a proportional increase in the chicken /3-actin cDNA that hybridized in this lane.
indirect induction of PFP mRNA by OKT3 mAb-stimulated IL-2 . OKT3 mAb
and IL-2 were also tested in combination to determinewhether their effects on PFP
mRNA expression were synergistic, additive, or antagonistic . After9 h of treatment,
IL-2 increased expression 3.2-fold and OKT-3 mAb increased expression 5 .2-fold,
while their combination enhanced PFP mRNA expression 5.4-fold over unstimu-
lated control CD3+ lymphocytes (Fig . 5 A) . Similarly, after 24 h a combination of
IL-2 and OKT-3 mAb was less than additive in stimulating PFP mRNA in CD3+
lymphocytes (data not shown) .
The Effect ofPMA and Ionomycin on PFPmRNA Expression in T Cells .
￿
T cell activa-
tion can be studied under conditions that bypass the requirement for crosslinking
oftheTCR/CD3 complex . Extracellular stimuli such as thecalcium ionophore, iono-
mycin, and the phorbol ester/protein kinase C (PKC) activator, PMA, have beenSMYTH ET AL .
￿
1275
used to identify important phosphatidylinositol-PKC signaling pathways in CTL
activation (19), granule release (20, 21)and cytolysis (22) . To define ifthesepathways
were important in the induction of PFP mRNA expression in CD3' T cells, the
effects ofPMA, ionomycin, or their combination were examined . It was clear that
PMA and ionomycin, either alone or in combination, were not capable of effecting
PFP mRNA expression in CD3+ T cells (Fig . 5 B), yet in combination they did
induce IFN-y expression (Fig . 5 B) and promote 3[H]TdR incorporation (Fig . 2) .
Thesedata indicate that nonspecifically increasing intracellular calcium, either alone
or in combination with PKC activation by PMA, has no effect upon PFP mRNA
expression in CD3+ T cells .
PFP mRNA Expression in CD3- LGL .
￿
LGL are CD3 - CD56' cells that contain
PFP (1, 5) and exhibitNK cell activity (23) . The majority of LGL are also CD16'
cells capable of mediating antibody-dependent cellular cytotoxicity (ADCC) (24) .
On purification of CD3 - CD56+ LGL, this population was analyzed by flow cy-
tometry to be <2% reactive with anti-CD3 mAb, 80% reactive with anti-CD56 mAb,
and 75% reactive with the anti-CD16 mAb. These purified CD3 - lymphocytes were
then cultured with or without 1,000 U/ml IL-2 for 6 h and their total cellular RNA
was examined by Northern analysis (Fig. 6,A and B) . Unlike CD3' lymphocytes,
unstimulated CD3 - CD56+ LGL had a moderate to high PFP mRNA expression
(Table I), consistent with their known high content of PFP (5) . Furthermore, PFP
mRNA levels were not increased after 6 h of stimulation by IL-2 (Fig . 6 A) (Table
1) . It should be noted that stimulation of CD3 - LGL with IL-2 for 24 and 72 h
(different donors) also did not increase the high resting PFPmRNA levels of these
cells (Table 1) .
An RIA for human IFN-y production wasperformed on the supernatants of these
IL-2-stimulated CD3- LGL cultures and the Northern blot was also hybridized
FIGURE 6.
￿
Expression ofPFP mRNA inhuman peripheral blood
CD3- CD56* LGL . This population was cultured for 6 h in the
presence (+) or absence (-) of IL-2 (1,000 U/ml) . Total cellular
RNAwas isolated from the cultured cells and Northern blot anal-
ysis was performed on 10 jug of RNA. The filter was hybridized
with a cDNA probe for (A) human PFP and (B) human IFN-y .1276
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TABLE I
Induction of PFP mRNA Expression in Lymphocyte Subsets
* Each experiment represents a different donor.
1 Expression ofPFP mRNA relative to untreated CD3' T cells equal to unity
was determined by quantitative densitometry ofNorthern blots (ratio ofPFP/
/3-actin expression, 10wg total cellular RNA/lane). In Exp. 5 the PFP mRNA
expression of IL-2-treated CD8' and CD4' T cell subsets was calculated
relative to IL-2-treated whole unfractionated CD3' T cells rather than un-
treated CD3' T cells .
with the human IFN-y probe. In accordance with LGL requiring a single signal
for IFN-y production (17), human IFN-y activity (2.6 U/ml) and human IFN-'r
mRNA (Fig. 6 B) were detected from LGL cultures stimulated for 6 h with IL-2
alone. Human IFN-y mRNA was not observed in unstimulated CD3- LGL nor
was there human IFN-y activity in the supernatant. Therefore, human peripheral
blood CD3- LGL contain elevated levels ofPFP mRNA that cannot be further in-
duced by stimulation with a 1,000 U/ml dose of IL-2.
IL-2 Induction of Cytotoxic Activity in CD3+ T Cells and CD3- CD16' NK Cells.
￿
The
observed inability of IL-2 to augment PFP expression in peripheral blood CD3-
LGL (Fig. 6 A) was somewhat unexpected, since it has been demonstrated that
CD3- CD16+ NK cells are predominantly responsible for IL-2-stimulated sponta-
neous cytotoxicity inhuman PBMC (23). However, all the previously described re-
sults on augmentation of NK cell cytotoxicity by IL-2 were derived by simply esti-
mating the direct killing against NK-sensitive or NK-resistant target cells. The
efficiency ofsuch direct killing will be affected by processes other than the cytolytic
potential ofthe killer cell, suchas cellular binding, recognition, andtriggering events
(25, 26). Indeed unfractionated human PBMC exhibited an augmented cytotoxic-
ity against the human myeloidleukemia cell line K562 aftera 16-h exposure toIL-2
Exp. Subset Treatment Dose
U/mt
Time
h
Relative
PFP mRNA
expression
1 * CD3 * CD56- - - 0 1 .0
CD3 - CD56' - - 0 12.8
2 CD3' CD56 - - - 6 1 .0
IL-2 1,000 6 6.6
CD3 - CD56' - - 6 18.4
IL-2 1,000 6 13.7
3 CD3' CD56 - - - 24 1 .0
CD3 - DC56' - - 24 15.4
IL-2 1,000 24 14.6
4 CD3' CD56 - - - 72 1 .0
CD3 - CD56' - - 72 12.9
IL-2 1,000 72 14.0
51 CD3' CD56 - IL-2 1,000 6 1 .0
CD3' CD8` IL-2 1,000 6 1 .3
CD3' CD4' IL-2 1,000 6 0.1in a dose-dependent manner (Fig. 7). However, no significant increase in NK cell
cytotoxic potential in these samples was observed in the parallel estimation ofredi-
rected cytotoxicity usingthe anti-CD16 mAb(3G8) x antinitrophenyl (NP) hapten
mAb heteroconjugate against a NP-modified murine T lymphoma EL-4. The di-
rect cytotoxicity of resting or IL-2-stimulated PBMC against K562 was mediated
by CD16' LGL, but not by CD3+ T cells, since cytotoxicity was abolished by de-
pletion ofCD16' cells from PBMC using anti-Leu-11b and complement (data not
shown). Asdescribed in ourprevious study(16), peripheral blood Tcellcytotoxicity
against NP-modified EL-4, usingthe heteroconjugate containing anti-CD3 (OKT-
3 mAb), could be rapidlyaugmented by exposureto IL-2 in a dose-dependent man-
ner (Fig. 7). Therefore, the cytotoxic potential ofperipheral blood T cells and NK
cells induced in response to IL-2 was in good correlation with IL-2-induced PFP
mRNA levels in these cells.
Discussion
By fractionating human peripheral blood lymphocytes into CD3+ CD8' and
CD3+ CD4' T cells and CD3- LGL, we have studied how PFP gene expression
is regulated. Our studies at the mRNA level were consistent with peripheral T cells
treated with IL-2-producing PFP (5, 27). The PFP mRNA expression in CD3+ T
cells was directly induced by IL-2 in a dose-dependent manner, independently of
DNA synthesis (Fig. 2) and new protein synthesis. The kinetics ofIL-2 stimulation
of PFP mRNA synthesis in these cells were very rapid (Fig. 1), and furthermore,
it was demonstrated that IL-2 induced PFP mRNA expression in CD8+, but not
in CD4+ T cells (Fig. 3). In addition, the expression of PFP mRNA in untreated
T cells (Fig. 1, 4, 5)waslikely to be representative of-20% ofresting CD8+ T cells
that have been shown to be reactive with anti-PFP mAbs (Okumura, K., unpub-
lished observations). This parallels the previous finding that all the detectable PFP
activity resides in the Lyt-2 + (CD8+) subset ofactivated murine or human periph-
eral T lymphocytes cultured in IL-2 (5, 27) and is consistent with our previous ob-
servations that the IL-2-induced cytolytic activity in peripheral blood T cells was
confined to the CD8+ subset (16). As the cytolytic activity ofcloned or primary CTL
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FIGURE 7.
￿
Cytotoxic activity
of human peripheral blood
CD3' T cells and CD16' NK
cells stimulated with IL-2. Un-
fractionated PBMC were cul-
tured with various doses ofIL-
2. After 16 h, cytotoxicity was
tested against NP-modified EL-
4 in the presence of OKT3 x
anti-NP (*) or 3G8 x anti-NP
(A)heteroconjugatedantibody
at an E/T ratio of 5:1 . Open
circles indicate basal cytotox-
icity in the absence of hetero-
conjugates. Open triangles in _
￿
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is generally due to CD8' T cells (28), the IL-2-inducible expression of PFP mRNA
in this subset further suggests that PFP has an essential function in CTL-mediated
target cell lysis. Although recently we have demonstrated that low levels of the p75
IL-2 receptor are preferentially expressed on peripheral blood CD8+ T cells (16),
these studies herein have indicated that an anti-IL-2 receptor p75 mAb can com-
pletely abrogate IL-2 induction of peripheral blood T cell PFP mRNA (Fig. 5) and
T cell cytotoxic potential. This suggests that IL-2 signaling via the p75 IL-2 recep-
tor is directly implicated in PFP gene expression in T cells.
The mechanisms of induction of PFP mRNA in CD3' T cells were also exam-
ined using OKT3 mAb or an activator of PKC (PMA) alone or in combination
with a calcium ionophore (ionomycin). OKT3 mAb induced PFP mRNA expres-
sion in T cells (Fig. 5A), although less rapidly than IL-2; however, bypassing cross-
linkingof the TCR/CD3 complex with the extracellular stimuli, PMA and ionomy-
cin, did not stimulate PFP mRNA induction in CD3' lymphocytes (Fig. 5 B).
Thus, although PKC activation has been reported to be required for CTL granule
release and triggering (19, 21), PKC activation by PMA and ionomycin does not
induce PFP mRNA expression in T cells. It is possible that IL-2 or OKT3 mAbs
do not induce PFP mRNA by activating the same PKC pathway as PMA or that
other protein kinases are involved in induction of PFP mRNA in T cells. Indeed,
the zeta-zetahomodimerof the T cell-CD3 complex has been demonstrated to have
tyrosine kinase activity (29), and recent studies have implicated tyrosine protein ki-
nase activity in the stimulation of T cells by IL-2 viathe 0 subunit ofthe IL-2 recep-
tor (30, 31). Future studies will be used to determine which protein kinases are in-
volved in PFP mRNA induction in T cells.
In contrast to CD3+ T cells, human peripheral blood CD3- CD56' LGL had
ahigh constitutive expression of PFPmRNA (Fig. 6A) with thelevels ofPFP mRNA
in the CD3- LGL 13-19 times that found in the CD3' T cells of the same donors
(Table I). By comparing and extrapolatingdata from a number of different donors
and calculating the expression of PFP mRNA relative to untreated CD3' T cell
populations, the levels of PFP mRNA in CD3- LGL were two to three times greater
than those in unfractionated CD3' T cells optimally stimulated with IL-2 (Table
I) . This difference becomes less significant when comparing CD3- LGL with
purified CD8' T cells.
Unlike Tcells, LGL PFP mRNA levels were not increased after6h ofstimulation
by IL-2 (Fig. 6 A). In addition, the cytolytic potential of peripheral blood CD3-
CD16' NK cells was not augmented by a brief exposure to IL-2 (Fig. 7). We be-
lieve this data is not in conflict with previous studies, which demonstrated the en-
hanced direct cytotoxicity of NK cells responding to IL-2 (23, 32). Our studies have
measured the redirected cytotoxic potential of NK cells after a brief exposure to
IL-2 in addition to simply determiningdirect killing against an NK-sensitive target
cell. We and others have also previously reported difficulty in enhancingthe ADCC
of NK cells (33, 34). A high constitutive expression of PFP mRNA in peripheral
blood LGL was implicated in its spontaneous cytotoxicity; however, an increase in
PFP mRNA expression was not involved in the enhanced spontaneous cytotoxicity
of LGL responding to IL-2. Therefore, although peripheral blood CD8' T cells and
CD3- LGL are similarly activated by IL-2 via its interaction with the IL-2 recep-SMYTH ET AL.
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for 0 chain (16, 35), the mechanisms responsible for the IL-2-induced cytotoxicity
of these cells appear to be quite different.
Summary
Our studies have analyzed pore-forming protein (PFP) mRNA expression in rest-
ing and stimulated human peripheral blood CD3 - large granular lymphocytes
(LGL), CD3 + T cells, and their CD4+ or CD8 + subsets. Signals that stimulate
T cells to develop cytotoxic activity (i.e., IL-2 or OKT3 mAb) led to the induction
ofPFP mRNA in T cells. The data indicated that IL-2 directly increased PFP mRNA
in the CD8+ subset of T cells, in the absence of new DNA or protein synthesis. Ab-
rogation of IL-2-induced PFP mRNA expression and cytotoxic potential of T cells
by the anti-p75 IL-2 receptor mAb suggested that low numbers of p75 IL-2 recep-
tors on CD8 + T cells were capable of transducing signals responsible for these IL-
2-induced effects. The induction ofT cell PFP mRNA via CD3, using OKT3 mAb,
was less rapid but greater than that caused by IL-2 ; however, a combination ofPMA
and ionomycin, which bypasses crosslinking of the TCR/CD3 complex, could not
mimic this increase in PFP mRNA levels in T cells. The role of second messenger
systems in regulating PFP mRNA expression remains to be determined. In con-
trast, high constitutive PFP mRNA expression was observed in CD3- LGL and
these mRNA levels could not be enhanced by stimulation with IL-2. The cytotoxic
potential of peripheral blood T cells and LGL induced in response to IL-2 corre-
lated with IL-2-induced PFP mRNA levels in these cells and was consistent with
PFP being one of several important molecules involved in the effector function of
cytotoxic lymphocytes.
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